证券之星消息，华大智造近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损 2.369亿元，同比增长60.57%。 业绩快报公告中对经营业绩和财务状况情况的说明： （一）报告期的经营情况、财务状况 本报告期，公司实现营业收入277,961.48万元，同比减少7.73%；实现归属于母公司所有者的净利 润-23,693.39万元，亏损同比减少60.57%；实现归属于母公司所有者的扣除非经常性损益的净利 润-37,784.42万元，亏损同比减少42.11%。 截至本报告期末，公司总资产1,023,960.79万元，同比减少0.73%；归属于母公司的所有者权益 763,247.77万元，同比减少3.27%。 （二）影响经营业绩的主要因素 1、报告期内营业收入及毛利贡献同比有所下滑，主要系：（1）市场竞争有所加剧，部分产品的销售价 格出现下滑；（2）产品销售结构变化，低通量系列基因测序产品的销量占比上升。 2、销售费用、管理费用、研发费用合计同比减少约19%，主要系公司制定了一系列"提质增效重回 报"措施，包括人效提升、研发聚焦、营销费用全周期管理等措施，导致公司相关的成本费用相比同期 减少。 3、 ...

CGI原本是华大智造海外核心运营主体。 2月24日，国产基因测序仪龙头华大智造（688114.SH）盘中股价涨幅超过1%。 2025年前三季度，华大智造归属于上市公司股东的净利润仍亏损1.2亿元。 伴随着这次出售CGI公司，华大智造也在调整在北美市场的运营方式，不再是正面"死磕"，而是通过授 权模式间接参与北美市场。 2025年9月，华大智造方面曾将CoolMPS测序技术及通用测序技术的海外专利、技术秘密及商标的独占 许可授权给了SwissRockets。 这次交易，华大智造方面又增加将StandardMPS测序技术（以下简称"StandardMPS"）及通用测序技术有 偿授权给SwissRockets，授权区域为美国以及加拿大。 与此同时，本次交易也通过反向授权安排保障华大智造对CGI公司205项专利的永久使用权，确保全球 业务技术连贯性。 前一晚，华大智造公布了一项出售资产计划，拟将剥离相关资产及负债后的全资孙公司 CompleteGenomics,Inc.（下称"CGI"）100%股权出售给瑞士公司SwissRockets，出售价约5000万美元。 原本CGI归属于华大智造全资子公司MGIR&DHK旗下 ...

Group 1: Economic Growth and Industrial Performance - The industrial added value of Zhengzhou is projected to grow by 9% year-on-year by 2025, with over 70% of industries experiencing growth [1][2] - Among the 38 major industrial categories, 27 are expected to maintain growth, increasing the growth rate by 8.9 percentage points compared to 2024 [2] - Key industries such as electronics and automotive manufacturing are expected to see added value growth of 16.2% and 11.9% respectively, contributing 6.4 percentage points to the overall industrial growth [2] Group 2: Leading Enterprises and Their Contributions - Leading companies like Yutong Bus, Antu Bio, and Super Fusion are driving industrial transformation in Zhengzhou [3] - Yutong Group is expected to sell 63,798 commercial vehicles in 2025, achieving a revenue of 49.38 billion yuan, a year-on-year increase of 11.4% [3] - Yutong's sales of new energy buses are projected to grow by 22.94%, with exports reaching 17,149 units, a 22.49% increase [3][4] Group 3: Research and Development Investments - Antu Bio's R&D investment reached 545 million yuan in the first three quarters of 2025, accounting for 17.42% of its revenue, with over 1,000 medical device registrations [4] - Super Fusion, established in Zhengzhou in 2021, aims for a revenue target of 50 billion yuan in 2025, with rapid growth in its server business [4] Group 4: Systemic Competitiveness and Future Outlook - Zhengzhou's economic total is expected to exceed 1.5 trillion yuan by 2025, reflecting both quantitative and qualitative transformations [5] - The city has become a pilot for comprehensive market-oriented reform, enhancing its development potential [6] - Zhengzhou's talent pool has surpassed 3.2 million, supported by initiatives like the "Zheng Gathering Talent Plan" [6]

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [3]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [3][4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [3]. Group 2: Financial Performance - Both target companies are currently in a high-investment R&D phase and have not yet achieved profitability. BGI Sanjian Qifa reported revenues of 60.74 million yuan and 27.99 million yuan for 2024 and January-October 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [5]. - BGI Xufeng's revenues were 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [5]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [5][6]. - The integration of these technologies is expected to enhance the company's competitive edge and profitability in the long term, with BGI Xufeng and BGI Sanjian Qifa projected to achieve profitability by 2026 and 2028, respectively [6][7]. Group 4: Valuation and Market Reaction - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [8]. - The acquisition pricing is considered reasonable compared to industry standards, with dynamic price-to-sales ratios around 3 times, significantly lower than comparable companies in their respective fields [9]. Group 5: Performance Commitments - Performance commitments have been established, with BGI Sanjian Qifa expected to achieve net profits of no less than 5 million yuan, 18.7 million yuan, and 26.4 million yuan from 2026 to 2028, totaling at least 50.1 million yuan [9]. - BGI Xufeng is expected to achieve net profits of no less than 5.2 million yuan, 24.6 million yuan, and 53 million yuan from 2028 to 2030, totaling at least 82.8 million yuan [9].

Core Viewpoint - BGI Genomics is making a significant move by acquiring 100% equity of two subsidiaries, Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its operations [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with Shenzhen Huada Sanjian Qifa valued at 158 million yuan and Hangzhou Huada Xufeng at 208 million yuan [3]. - BGI Genomics plans to inject 70 million yuan and 60 million yuan into the respective companies for operational expansion and working capital [3]. - A loan of 70 million yuan will be provided to Hangzhou Huada Xufeng at a 2.5% interest rate for three years to repay existing debts [3]. Group 2: Financial Performance - Both acquired companies are currently in a high-investment R&D phase and have not yet achieved profitability, with significant losses reported [5][7]. - Financial data shows that Shenzhen Huada Sanjian Qifa had revenues of 60.74 million yuan and 27.99 million yuan for 2024 and the first ten months of 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [7]. - Hangzhou Huada Xufeng reported revenues of 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [7]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive technology chain that includes short-read, long-read, and spatial omics technologies, positioning BGI Genomics as a unique player in the global market [6][8]. - The integration of these technologies is expected to enhance customer service capabilities and meet diverse research needs [8]. - The companies are projected to achieve profitability by 2026 and 2028, respectively, with specific profit commitments outlined [10]. Group 4: Valuation and Market Perception - The valuation of the acquired companies shows a high appreciation rate, with Shenzhen Huada Sanjian Qifa at 2460.66% and Hangzhou Huada Xufeng at 296.55% [9]. - The rationale behind the high valuation is attributed to the companies' technological advantages and potential strategic value in the market [9]. - The acquisition is viewed as a cost-effective move for BGI Genomics, aligning with industry standards and providing a competitive edge [9].

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [2][4]. Group 1: Acquisition Details - The total transaction price for the acquisition is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [4]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [4]. Group 2: Financial Performance and Projections - Both BGI Sanjian Qifa and BGI Xufeng are currently in the R&D phase and have not yet achieved profitability, with projected revenues of 607.43 million yuan and 279.96 million yuan for BGI Sanjian Qifa in 2024 and 2025, respectively [6]. - BGI Xufeng is expected to generate revenues of 440.23 million yuan and 661.38 million yuan in the same periods, with significant net losses reported [6]. - Profitability is anticipated for BGI Sanjian Qifa and BGI Xufeng by 2026 and 2028, respectively, with performance commitments set for net profits during these years [7][11]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [6][8]. - The integration of these technologies is expected to enhance BGI Genomics' competitive edge and profitability in the long term, potentially serving as a new growth engine [7][8]. - The strategic alignment of BGI Sanjian Qifa's spatial omics with BGI Genomics' existing platforms is anticipated to attract new customers and meet complex research needs [8]. Group 4: Valuation and Market Considerations - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [9][10]. - The assessment of these companies considers not only tangible assets but also intangible resources such as brand, technology, and customer relationships [10]. - The transaction is viewed as having a strong cost advantage compared to industry peers, with dynamic price-to-sales ratios around 3 times lower than comparable companies in their respective fields [10].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. plans to acquire 100% equity of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd. for a total price of 365.7 million yuan, aiming to enhance its capabilities in spatial omics and nanopore sequencing technologies [2][5][12]. Transaction Overview - The acquisition involves cash payment for the equity of the two companies, with the total transaction price set at 365.7 million yuan, comprising 158 million yuan for Sanjian Qifa and 207.7 million yuan for Xifeng [2][5]. - Following the acquisition, BGI Intelligent Manufacturing will inject 70 million yuan into Sanjian Qifa and 60 million yuan into Xifeng to support their operations and business expansion [3][6]. Technology and Intellectual Property - Sanjian Qifa will acquire intellectual property rights related to spatial omics technology, with a transaction price of 65.34 million yuan [4][12]. - Xifeng will acquire intellectual property rights related to nanopore sequencing technology, with a transaction price of 56.17 million yuan [4][12]. Performance Commitment - BGI Technology, the counterparty, has made performance commitments regarding the profitability of the acquired companies. If the companies fail to meet the promised net profit during the commitment period, BGI Technology will provide cash compensation [4][12]. Financial Impact - The transaction is expected to have a short-term impact on the company's operating profits due to the acquired companies being in the R&D phase and not yet profitable. However, the long-term potential for innovation and commercialization is significant [8][12]. - The acquisition will not adversely affect the company's cash flow, as it has sufficient cash reserves and a strong cash-generating ability [8][12]. Strategic Importance - This acquisition is a strategic move to integrate cutting-edge technologies in spatial omics and nanopore sequencing, enhancing the company's competitive edge in the gene sequencing market [8][19]. - The combined capabilities will allow the company to offer comprehensive solutions from library construction to sequencing and data analysis, significantly improving service capabilities [18][21]. Market Positioning - BGI Intelligent Manufacturing aims to secure a leading position in the global sequencing market by integrating both short-read and long-read sequencing technologies, thus enhancing its strategic initiative and market competitiveness [19][20]. Approval Process - The transaction has been approved by the company's board of directors and will require further approval from the shareholders' meeting, with related parties abstaining from voting [7][23].

联检科技（301115.SZ）1月29日在投资者互动平台表示，公司不直接提供医疗方面的检测服务。公司子 公司苏州赛宝可提供医疗相关设备的计量校准服务，服务于众多医疗器械厂、药厂。公司子公司深圳中 认通测可提供基因测序仪、测量设备、体外诊断设备的EMC测试服务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：针对我国在尼帕病毒方面的检测能力，国家传染病医 学中心、复旦大学附属华山医院感染科主任张文宏教授表示："二代测序检测能力没有问题。"请问贵公 司有没有医疗方面的检测能力和业务，未来对医疗检测业务有什么规划？ 每经AI快讯，有投资者在投资者互动平台提问：针对我国在尼帕病毒方面的检测能力，国家传染病医 学中心、复旦大学附属华山医院感染科主任张文宏教授表示："二代测序检测能力没有问题。"请问贵公 司有没有医疗方面的检测能力和业务，未来对医疗检测业务有什么规划？ 联检科技（301115.SZ）1月29日在投资者互动平台表示，公司不直接提供医疗方面的检测服务。公司子 公司苏州赛宝可提供医疗相关设备的计量校准服务，服务于众多医疗器械厂、药厂。公司子公司深圳中 认通测可提供基因测序仪、测量设备、 ...

格隆汇1月29日丨联检科技(301115.SZ)在投资者互动平台表示，公司不直接提供医疗方面的检测服务。 公司子公司苏州赛宝可提供医疗相关设备的计量校准服务，服务于众多医疗器械厂、药厂。公司子公司 深圳中认通测可提供基因测序仪、测量设备、体外诊断设备的EMC测试服务。 ...

Core Viewpoint - The company, BGI Genomics (stock code: 688114.SH), has released its earnings forecast for 2025, indicating a significant reduction in losses compared to the previous year, driven by operational improvements and favorable currency exchange impacts [2][4]. Financial Performance - The company expects a net profit attributable to shareholders of between -221 million to -273 million yuan for 2025, a notable improvement from a loss of 601 million yuan in the previous year, representing a year-on-year reduction of approximately 54.56% to 63.22% [4]. - After excluding non-recurring gains and losses, the anticipated net profit is projected to be between -322 million to -397 million yuan, compared to a loss of 653 million yuan last year, indicating a year-on-year improvement of about 39.18% to 50.67% [4]. Reasons for Performance Changes - The company has implemented measures focused on "quality improvement, efficiency enhancement, and return on investment," leading to a decrease in overall costs compared to the previous year [5]. - Currency exchange gains from holding foreign currency monetary items have increased due to fluctuations in the US dollar and euro [5]. - The company has reversed tax provisions related to previous years' uncertain tax disputes, resulting in a reduction in income tax expenses [5]. Company Overview - BGI Genomics is a domestic manufacturer focused on core tools and high-end equipment in life sciences, primarily engaged in gene sequencing and related laboratory automation equipment [6]. - The company emphasizes independent research and development, providing foundational technical equipment and systematic solutions for research institutions, clinical testing laboratories, and industrial clients [6]. Business Segments Gene Sequencing Business - The gene sequencing business is the core segment, continuously upgrading products and reagents to enhance sequencing efficiency, coverage, and application adaptability [7]. - In 2024, the company plans to launch the next-generation sequencing reagent StandardMPS 2.0, along with upgrades to several core sequencing platforms, enhancing their applicability across various research and clinical needs [9]. Laboratory Automation Business - The company is advancing towards systematic and intelligent upgrades in laboratory automation, focusing on key processes such as sample handling, experimental execution, and data analysis [10]. - New products like αLabStudio, αLabRobot, and αCube are being introduced to improve sample management efficiency and experimental stability [12]. New Business Segment - The new business segment focuses on multi-omics tools, ultrasound imaging, and intelligent robotics, aiming to meet cutting-edge research and clinical transformation needs [13][15]. - The company is expanding its capabilities in cell omics, spatiotemporal omics, and proteomics, enhancing high-throughput data collection and analysis [15][16].